scispace - formally typeset
L

Lamont Booker

Researcher at Virginia Commonwealth University

Publications -  8
Citations -  2061

Lamont Booker is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: Cannabinoid receptor & Cannabinoid. The author has an hindex of 7, co-authored 8 publications receiving 1889 citations. Previous affiliations of Lamont Booker include VCU Medical Center.

Papers
More filters
Journal ArticleDOI

Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

TL;DR: 2-AG endogenously modulates several behavioral processes classically associated with the pharmacology of cannabinoids and point to overlapping and unique functions for 2-AG and anandamide in vivo, indicating a functional segregation of endocannabinoid signaling pathways in vivo.
Journal ArticleDOI

Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo

TL;DR: A selective and efficacious dual FAAH/MAGL inhibitor is described and it is shown that this agent exhibits broad activity in the tetrad test for CB1 agonism, causing analgesia, hypomotilty, and catalepsy, indicating that AEA and 2-AG signaling pathways interact to regulate specific behavioral processes in vivo, including those relevant to drug abuse.
Journal ArticleDOI

Synergy between Enzyme Inhibitors of Fatty Acid Amide Hydrolase and Cyclooxygenase in Visceral Nociception

TL;DR: The results of the present study suggest that FAAH represents a promising target for the treatment of visceral pain, and a combination of FAAH inhibitors and NSAIDs may have great utility to treat visceralPain, with reduced gastric toxicity.
Journal ArticleDOI

The fatty acid amide hydrolase (FAAH) inhibitor PF‐3845 acts in the nervous system to reverse LPS‐induced tactile allodynia in mice

TL;DR: Blockade of the catabolic enzyme fatty acid amide hydrolase (FAAH) elevates AEA levels and elicits antinociceptive effects, without the psychomimetic side effects associated with Δ9‐tetrahydrocannabinol (THC).